James A. Keyte
Fordham Competition Law Institute - FCLI (New York), The Brattle Group (New York)
Director of Global Development
As the Director of Global Development, Mr. Keyte plays a lead role in growing Brattle’s antitrust practice and defining a new level of quality for economic consulting. His extensive practical experience, along with his deep antitrust expertise, gives Brattle a competitive advantage in producing top quality expert work product across all competition subject areas. Mr. Keyte is directly engaged in marketing, training, and quality review across all of Brattle’s competition and antitrust engagements both in the U.S. and globally. Mr. Keyte previously spent more than twenty years as a partner at Skadden, where he handled a wide variety of antitrust litigation, transactions, and advisory matters across numerous industries. He led high-profile antitrust cases involving alleged price-fixing, monopolization, mergers, intellectual property licensing, and sports-related matters, including class actions. He was also involved in a number of high-profile mergers, several of which involved litigation challenges by the DOJ and FTC. Mr. Keyte is the Director of the Fordham Competition Law Institute (FCLI), which he will continue to lead, and has published more than 50 articles related to antitrust across a wide range of topics, including on the subject of expert testimony. He is an adjunct professor at Fordham Law School, a former editor of Antitrust Law Journal, and currently serves as editor of Antitrust Magazine. He holds a J.D. from Loyola Law School (Law Review) and a B.A. from Harvard University (cum laude).
Distinctions
Nominee, 2019 Antitrust Writing Awards: Academic, Unilateral Conduct
Nominee, 2016 Antitrust Writing Awards: Academic, Mergers
Nominee, 2015 Antitrust Writing Awards: Business, Concerted Practices
Nominee, 2014 Antitrust Writing Awards: Academic, Private Enforcement
Nominee, 2013 Antitrust Writing Awards: Academic, Mergers
Winner, 2012 Antitrust Writing Awards: Academic Readers Award
Linked authors
Clifford H. Aronson
Skadden, Arps, Slate, Meagher & Flom (New York)
Alec Y. Chang
Skadden, Arps, Slate, Meagher & Flom (Palo Alto)
Ian G. John
Kirkland & Ellis (New York)
Gary A. MacDonald
Skadden, Arps, Slate, Meagher & Flom (Washington DC)
Steven C. Sunshine
Skadden, Arps, Slate, Meagher & Flom (Washington DC)
Neal R. Stoll
Skadden, Arps, Slate, Meagher & Flom (New York)
Benjamin C., Jr. Crisman
Skadden, Arps, Slate, Meagher & Flom (Washington DC)
Filip Kubik
European Commission (Brussels)
6078 | Conferences
Videos
Articles
2486 Bulletin
211
I. Introduction The application of competition laws to sports has a long tradition in the United States and increasingly is becoming a major focus of the EU Member States and the EU Commission. But it would be naïve to assume that the enforcement or substantive application of U.S. and EU (...)
682
This article has been nominated by the Business Steering Committee for the business category, mergers section of the 2012 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On October 31, 2011, the U.S. District Court for the District of Columbia is sued (...)
460
United States v. H&R Block: The DOJ Invokes Brown Shoe to Shed the Oracle Albatross* On November 10, 2011, the U.S. Department of Justice won its first fully litigated merger challenge since its 2004 defeat in United States v. Oracle Corp. In the interim, the Federal Trade Commission had (...)
257
On March 29, 2010, Judge Mitchell S. Goldberg upheld antitrust lawsuits filed by the Federal Trade Commission (FTC) and private plaintiffs against drug maker Cephalon, Inc. (Cephalon), alleging that Cephalon conspired with four generic drug manufacturers to delay generic competition for the (...)
329
On February 22, 2010, Judge Thomas W. Thrash, Jr. dismissed the Federal Trade Commission’s (FTC) antitrust lawsuit alleging that Solvay Pharmaceuticals (Solvay) conspired with generic drug makers Watson Pharmaceuticals (Watson) and Par Pharmaceuticals (Par) to delay generic competition for the (...)
89
On April 27, 2009, the Federal Trade Commission adopted final rules amending Parts 3 and 4 of its Rules of Practice. The adoption of these rules is a culmination of efforts going back a couple of years to make changes that would expedite adjudications of allegedly anti-competitive merger (...)
245
On March 18, 2009, Judge Collyer of the United States District Court for the District of Columbia released the public version of a significant opinion supporting her order granting the FTC a preliminary injunction in connection with the proposed $1.4 billion merger of CCC Information Systems (...)
213
Continuing a trend of increasing aggressiveness in antitrust enforcement, the Federal Trade Commission (FTC) is seeking disgorgement in a challenge to Ovation Pharmaceutical Inc.’s acquisition of the drug NeoProfen®, filed in the Minnesota District Court on Dec. 16, 2008. In the past, the FTC has (...)
Books
Price
250€00
2015 Competition Case Law Digest - A Synthesis of EU and National Leading Cases
This second edition of the Digest is enriched with a selection of more than 50 essays on European competition cases from the 27 European Union Member States, EU law, and US law. Each essay (...)
Date
30 November 2015
Price
250€00
Price
180€00
William E. Kovacic: An Antitrust Tribute Liber Amicorum Vol. I
Les États-Unis ne semblent pas avoir développé la tradition du liber amicorum dans le cercle des juristes. Le présent ouvrage est donc un coup d’essai extrêmement réussi, pour ne pas dire “un coup de (...)
Date
12 December 2012
Price
180€00
